ReiThera collaborates with the MAGIC consortium to support the development of gene therapies for muscular dystrophies

ReiThera will be involved in setting up both Upstream Process (USP) and Downstream Process (DSP) conditions for GMP-compatible manufacturing of an AAV candidate specifically retargeted to muscle cells with an innovative technological approach, and to produce batches for preclinical studies.

London, July 11, 2023 – We are thrilled to announce the launch of the groundbreaking project “MAGIC” (Next-generation Models And Genetic therapIes for rare neuromusCular diseases). This ambitious four-year initiative jointly funded (~9.5M EUR) by Horizon Europe and UK Research and Innovation (UKRI) brings together 15 international partners to transform the treatment landscape for muscular dystrophies, which are severe genetic disorders with limited treatment options.